Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

UBS Group AG’s indirect holding has increased to 5.43 percent

Tikkurila OyjMajor Shareholder Announcement21 April 2021 at 3.55 p.m.(EEST) Tikkurila Oyj (business ID 0197067-4) has on 21 April 2021 received a notification pursuant to the Finnish Securities Markets Act, Chapter 9, Section 10, from UBS Group AG. The indirect holding of the funds and accounts managed by UBS Group AG in the shares of Tikkurila Oyj has increased above 5 percent and is now 5.43% as a consequence of the trades executed on April 20, 2021. UBS Group AG’s position according to their notification: Total positions of person(s) subject to the notification obligation:

Crunchfish publishes the 2020 Annual Report

Crunchfish’s annual report for 2020 is now available via the company’s website. On May 12th, Crunchfish will also host a live presentation of the company’s annual report, the business development and the plans ahead for the company.The annual report can be downloaded here  and may also be distributed in printed format upon request. The annual report is available in Swedish only. Invitation to a presentation of the annual reportOn May 12[th], at 10 am CET, Crunchfish will host a live presentation of the

Mount Sinai Hospital in New York joins RhoVac’s Phase IIb Study in Prostate Cancer

RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, April 21[st] 2021, that the prestigious Mount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac’s clinical phase IIb study, “BRaVac”, in prostate cancer.Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States, and it is widely recognised and one of the leading hospitals in the US, and indeed in the world, and as such RhoVac is extremely proud to declare its participation in the BRaVac trial. The

NOTICE OF THE ANNUAL GENERAL MEETING OF ZINZINO AB (publ.)

The shareholders of Zinzino AB (publ), org. no. 556733-1045 (the “Company”) are hereby invited to participate in the Annual General Meeting on Thursday, 20 May 2021.2021 ANNUAL GENERAL MEETING FORMATIn light of the extraordinary situation society finds itself in due to coronavirus, the format of the 2021 Annual General Meeting of Zinzino AB will be adapted accordingly. Taking into account the health of both the shareholders and the company representatives as well as ongoing efforts to limit the spread of infection, the Annual General Meeting will be held without the possibility of

Bluefors' founders and DevCo form long-term partnership

· Bluefors’ founders and DevCo form long-term partnership to support Bluefors’ next growth phase · DevCo becomes a co-owner of Bluefors and brings complementary know-how related to building world leading companies · Bluefors’ founders will continue as significant co-owners and in their current operational roles. Their contribution will also be instrumental in the next growth phase of Bluefors · Kimmo Alkio (CEO of TietoEVRY) and Juha Räisänen join the board of Bluefors (Alkio as Chairman). Further, Ilkka Paananen will become strategic advisor to Bluefors’ board Bluefors’

Shipping bodies call on world leaders to bring forward discussions on global market-based measures

· Ahead of President Biden’s climate summit, shipping industry bodies representing the majority of maritime trade have called on world leaders to quickly commence deliberations on how mandatory market-based measures (MBMs) could be implemented for international shipping. · In a joint submission to the United Nations, the bodies are asking member states at the International Maritime Organization (IMO) to bring forward discussions on the development of market-based mechanisms to help decarbonise global shipping. · Industry is asking governments to bring discussions on carbon pricing

Stayble provides update on the ongoing Phase 2b study due to the covid-19 pandemic

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to the covid-19 pandemic and the strict pandemic rules with several lock-downs in all study countries. Under current conditions, the company is expected to be able to report study results during the second half of 2022, which is later than previously communicated.“We have been pleased to note that patients continue to be recruited in our study and there is great enthusiasm among the investigators at the participating clinics. At

FIA Smart  Driving Challenge season 2021 is taking off

The Fédération Internationale de l'Automobile (FIA) is launching the Season 2021 of the FIA Smart Driving Challenge, a challenge inviting motorists across the world to adopt smarter, safer, and eco-friendlier behaviour at the wheel.The FIA Smart Driving Challenge (FIA SDC), supported by several FIA Member Clubs, is free and open to all motorists who can take part using all types of cars (electric, hybrid or fuel). To join, participants should download the FIA Smart Driving Challenge app on their smartphone and connect it to their car via Bluetooth. They will then be invited to choose one

Notice to Annual General Meeting in Bluefish Pharmaceuticals AB (publ) - Swedish

Kallelse till årsstämma i Bluefish Pharmaceuticals ab (publ) Aktieägarna i Bluefish Pharmaceuticals AB (publ), org. nr. 556673–9164, (”Bolaget”) kallas härmed till årsstämma onsdagen den 19 maj 2021 Till följd av Covid-19 pandemin har styrelsen beslutat att årsstämman skall genomföras utan fysisk närvaro av aktieägare, ombud och utomstående och att utövande av rösträtt endast kan ske genom poströstning före årsstämman. REGISTRERING OCH ANMÄLAN För att ha rätt att deltaga genom poströstning i årsstämman ska aktieägare dels vara införd i den av Euroclear Sweden AB förda aktieboken

QLIFE signs exclusive European distribution agreement with Aidian

Qlife has signed an exclusive European distribution agreement with Aidian Oy, for the Egoo.Health device and Sars-CoV2-capsule for the clinical diagnostics market. Aidian Oy is a market leading In Vitro Diagnostics (IVD) company based in Finland.The agreement covers a range of European countries, including Sweden, Norway, Finland, Germany, Netherlands, Belgium, Luxembourg, Austria, Switzerland, Poland, Czech Republic, Hungary, Slovakia, Romania, Slovenia, and Baltics, and applies immediately. Aidian is a market leader in the clinical diagnostics market offering solutions and services

Interim report January—March 2021: Good order intake paves the way for higher sales and improved earnings

· Order intake increased by 3% to 417 MSEK (406). · Net sales amounted to 351 MSEK (395). · EBIT was 4.6 MSEK (8.4). · Profit after tax of 1.6 MSEK (5.2). · Earnings per share were 0.06 SEK (0.19). · Acquisition of ELTEC of Germany strengthens Westermo’s train offering.     COMMENTS FROM CEO PER SAMUELSSON “The progress of beijer group’s orders in the first quarter underscores the economic recovery, with increased demand. Order intake in the first quarter 2021 increased on  the previous quarter, and the first quarter of the previous year. We also note that order

Bellman Group AB acquires Norrvidinge

Bellman Group has signed an agreement to acquire Norrvidinge[1], a company providing haulage and machine services, as well as civil engineering materials, across southern Sweden. The Norrvidinge group has a similar structure to Bellman Group, and the acquisition is another step in the strategy of creating a complete provider for the construction and civil engineering sector. Bellman Group did not previously have a presence in southern Sweden, where Norrvidinge has very strong positioning. The purchase consideration is SEK 283 m, paid in cash and through a vendor take-back. A

Herantis Pharma Oyj : Managers' Transactions – Hilde Furberg

Herantis Pharma Plc Company release 21 Apr 2021 at 2:00pm EETHerantis Pharma Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirement Name: Furberg, Hilde Position: Member of the Board/Deputy member Issuer: Herantis Pharma Plc LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20210421111816_3 ____________________________________________ Transaction date: 2021-04-20 Venue: FIRST NORTH FINLAND (FNFI) Instrument type: SHARE ISIN:

Interim report Q1 2021

January – March · Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. ·  Revenues amounted to MSEK 713.0 ( 793.6), corresponding to a decrease of -10% for the period. · The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of +7%. · EBIT (Operating Profit) amounted to MSEK 128.1 (104.1), corresponding to growth of 23%. · EBITDA* amounted to MSEK 259.8 (209.3)

Crunchfish signs evaluation agreement with Chinese provider of AR-glasses

Crunchfish Gesture Interaction AB ("Crunchfish") enters an Evaluation License Agreement with Extremesight Technology Ltd in China, to evaluate Crunchfish’s XR Skeleton gesture control software for their new AR-glasses. Extremesight will pay a smaller fee for the evaluation license and support services that will give the company access to Crunchfish XR Skeleton to integrate and evaluate for commercial use as a next step.Extremesight is developing Augmented Reality (AR) glasses with full AR capabilities, where gesture interaction may be used as an interaction paradigm. Crunchfish XR

Alliance model does not work without trust

In an alliance, trust between the parties is what makes the project organisation work. Trust is built through openness and interaction.  An alliance is a project model based on transparent cooperation. The project organisation formed by the parties is mutually responsible for the planning and construction of the project. The risks and benefits are also shared, which means that everyone wins or loses. Alliances are mainly used in challenging projects involving many uncertainties and stakeholders, such as industrial projects (Naantali CHP), hospital projects (Lapland Central Hospital

Bladder cancer study results accepted for publication in Nature Communications

Hamlet Pharma is proud to announce that the report of the phase I/II bladder cancer trial has been accepted for publication in Nature Communications; a leading international journal.The paper is entitled "Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex" andhas been accepted for publication in Nature Communications. The Nature journals are extremely competitive and only accept innovative science of highest quality and with significant interest for a discerning audience. The journals are widely read, with a high impact. The paper analyses the structure of

GOBIO places orders for 100 Ironhand[®] systems

EUROPE TECHNOLOGIES' GOBIO has signed an agreement for purchasing 100 Ironhand[®] systems over a period of ten months. The order will secure the delivery of Ironhand systems to meet the high demand in the French market.[Ironhand Soft Active Exoskeleton] Bioservo and GOBIO have worked closely together since 2019 and have concluded many successful projects leading to an increasing demand from several industry segments. GOBIO is now able to commit on much larger quantities and putting in place an agreed delivery schedule will allow Bioservo to secure a more stable production level. “The

AFRY signs agreement to acquire Optima Nexus Consulting in Switzerland

The acquisition of Optima Nexus is in line with AFRY’s digitalisation strategy and will strengthen the capabilities within digital asset management.Optima Nexus is a Swiss-based digital company specialised in strategic asset management. The company has developed a digital asset management framework, Mobility Infrastructure Asset Management (MIAM), as well as a corresponding software suite to evaluate large asset portfolios. Optima Nexus focuses on advisory consulting in strategic asset management implementation of MIAM software suite, and support asset managers to evaluate the funding

Covid 19 prevention in public places and transports - Talkpool, Redytel, Netmore and Senseair form indoor air quality alliance

We are all concerned about the spread of Covid 19 in society - which to a large degree is transmitted by aerosols in the air we breathe. New technologies related to Internet of Things have allowed large scale deployment of sensors that are able to monitor air quality in real time. Based on positive initial results from pilot projects the parties have decided to form an indoor air quality alliance with the aim to provide solutions that can prevent the spread of Covid 19 and support a safe reopening of society. The relationship between CO2 levels and air quality has been documented for

Press invitation to Vattenfall’s Annual General Meeting 2021

The Annual General Meeting (AGM) of Vattenfall AB will take place on Wednesday 28 April at CEST 09.30. Due to the current situation the AGM can only be followed online at group.vattenfall.com/seThe AGM is held in Swedish and will be broadcast live on the web. A recorded version will be published later during the day at group.vattenfall.com/se In order to ask questions to the Vattenfall Board or Executive Directors of Vattenfall via telephone please call in 10-15 minutes before conference start: Sweden: +46 (0)8 5051 0031 UK: +44 (0) 207 107 06 13 In order to ask questions via

Diamyd Medical to present at Precision Medicine conference

CEO Ulf Hannelius has been invited to give a talk at the “Precision medicine – From patient to lab and back again” conference organized by the Copenhagen Bioscience Cluster, a Novo Nordisk foundation initiative.The talk, which is based on an abstract submitted to the conference entitled “Developing data-driven precision therapies for Type 1 diabetes”, will focus on how the data collected in Diamyd Medical’s clinical trials together with scientific advances in the field have informed the development of the precision medicine diabetes vaccine Diamyd[®] for the treatment of type 1 diabetes.

Bulletin from Scandic’s extraordinary general meeting

The extraordinary general meeting of Scandic was held on Wednesday April 21, 2021.  In order to mitigate the spread of Covid-19, the extraordinary general meeting was conducted by advance voting only, without physical presence of shareholders, proxies and third parties.The extraordinary general meeting resolved to approve the board of directors’ resolution on March 26, 2021, that the loan raised by Scandic at par value of not more than SEK 1,800,000,000 in total shall be convertible into shares in Scandic by way of an issue of convertible bonds. More information about the resolution is

There are no items matching the current filter
There are no more items matching the current filter
Back to top